Steven Denyer1, Abhiraj D Bhimani1,2, Shashank N Patil1, Andrew Mudreac1, Mandana Behbahani1, Ankit I Mehta3. 1. Department of Neurosurgery, University of Illinois at Chicago College of Medicine, 912 S. Wood Street, 4N NPI, Chicago, IL, 60612, USA. 2. Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Department of Neurosurgery, University of Illinois at Chicago College of Medicine, 912 S. Wood Street, 4N NPI, Chicago, IL, 60612, USA. ankitm@uic.edu.
Abstract
INTRODUCTION: Primary intracranial germ cell tumors are rare neoplasms derived from gonadal cells. They are categorized as germinoma, non-germinomatous germ cell tumor (NGCCT), or teratoma, with the latter two sparking controversy regarding the role of different treatment strategies. We provide the largest multicenter analysis of treatment outcomes for iGCTs to date. METHODS: The Surveillance, Epidemiology, and End Result (SEER) database were used to record patient demographics, tumor, and treatment characteristics. Cox proportional hazards model and multiple comparisons for the Logrank test with Sidak correction was applied to compare the different treatment regimens and survival. RESULTS: 1043 iGCT cases were divided into three cohorts of Germinoma, Malignant Teratoma (MT), and NGGCT. The mean age was 17.7 years for germinoma, 9.5 years for MT, and 14.4 years for NGGCT groups. Males comprised 77% of overall patient population. For Germinomas, both biopsy (hazard ratio [HR] = 4.6) and resection (HR = 14.1) had significantly worse survival outcomes compared to solo radiation therapy, with no difference between radiation and chemotherapy. For MT, no treatment combination had significantly different survival outcomes compared to resection alone. For NGGCTs, resection + chemotherapy + radiotherapy (HR = 0.012) and resection + chemotherapy (HR = 0.0049) had significantly better survival compared to resection alone. CONCLUSION: In germinomas, radiotherapy alone had superior survival outcomes compared to biopsy and resection, but no change in survival when compared to chemotherapy alone. Addition of radiotherapy or chemotherapy did not improve survival in MTs when compared to resection alone. Adding chemotherapy in NGGCT patients undergoing resection improved survival compared to resection alone.
INTRODUCTION: Primary intracranial germ cell tumors are rare neoplasms derived from gonadal cells. They are categorized as germinoma, non-germinomatous germ cell tumor (NGCCT), or teratoma, with the latter two sparking controversy regarding the role of different treatment strategies. We provide the largest multicenter analysis of treatment outcomes for iGCTs to date. METHODS: The Surveillance, Epidemiology, and End Result (SEER) database were used to record patient demographics, tumor, and treatment characteristics. Cox proportional hazards model and multiple comparisons for the Logrank test with Sidak correction was applied to compare the different treatment regimens and survival. RESULTS: 1043 iGCT cases were divided into three cohorts of Germinoma, Malignant Teratoma (MT), and NGGCT. The mean age was 17.7 years for germinoma, 9.5 years for MT, and 14.4 years for NGGCT groups. Males comprised 77% of overall patient population. For Germinomas, both biopsy (hazard ratio [HR] = 4.6) and resection (HR = 14.1) had significantly worse survival outcomes compared to solo radiation therapy, with no difference between radiation and chemotherapy. For MT, no treatment combination had significantly different survival outcomes compared to resection alone. For NGGCTs, resection + chemotherapy + radiotherapy (HR = 0.012) and resection + chemotherapy (HR = 0.0049) had significantly better survival compared to resection alone. CONCLUSION: In germinomas, radiotherapy alone had superior survival outcomes compared to biopsy and resection, but no change in survival when compared to chemotherapy alone. Addition of radiotherapy or chemotherapy did not improve survival in MTs when compared to resection alone. Adding chemotherapy in NGGCT patients undergoing resection improved survival compared to resection alone.
Authors: Soumen Khatua; Girish Dhall; Sharon O'Neil; Rima Jubran; Judith G Villablanca; Araz Marachelian; Arti Nastia; Robert Lavey; Arthur J Olch; Ignacio Gonzalez; Floyd Gilles; Marvin Nelson; Ashok Panigrahy; Gordon McComb; Mark Krieger; Jing Fan; Richard Sposto; Jonathan L Finlay Journal: Pediatr Blood Cancer Date: 2010-07-15 Impact factor: 3.167
Authors: C Balmaceda; G Heller; M Rosenblum; B Diez; J G Villablanca; S Kellie; P Maher; V Vlamis; R W Walker; S Leibel; J L Finlay Journal: J Clin Oncol Date: 1996-11 Impact factor: 44.544
Authors: H J Hoffman; H Otsubo; E B Hendrick; R P Humphreys; J M Drake; L E Becker; M Greenberg; D Jenkin Journal: J Neurosurg Date: 1991-04 Impact factor: 5.115
Authors: Stewart J Kellie; Hayden Boyce; Ira J Dunkel; Blanca Diez; Marc Rosenblum; Lynette Brualdi; Jonathan L Finlay Journal: Pediatr Blood Cancer Date: 2004-08 Impact factor: 3.167
Authors: J R Crawford; M R Santi; G Vezina; J S Myseros; R F Keating; D A LaFond; B R Rood; T J MacDonald; R J Packer Journal: Neurology Date: 2007-05-15 Impact factor: 9.910
Authors: Matthew J Murray; Shivani Bailey; Katja Heinemann; Jillian Mann; Ulrich K Göbel; Frank Saran; Juliet P Hale; Gabriele Calaminus; James C Nicholson Journal: Int J Cancer Date: 2017-05-15 Impact factor: 7.396
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Sultan M Zain; Kanish Mirchia; Kristyn Galbraith; Michael A Galgano; Mijung Lee; Timothy E Richardson; Kavya Mirchia Journal: Radiol Case Rep Date: 2022-07-13